Saghmos Therapeutics Announces Issuance of Patent in Japan for Phase 3-Ready Cardiorenal Metabolic Modulator ST-62516
2024年5月14日 - 11:05PM
ビジネスワイヤ(英語)
Patent has broad claims for the Reduction of Acute Kidney
Injury in Patients with Chronic Kidney Disease Undergoing
Procedures with Contrast Dyes
Provides exclusivity through 2037
Saghmos Therapeutics, Inc. (Saghmos), a privately held
biopharmaceutical company, announced that the Japanese Patent
Office has issued Japanese Patent No. 7474463 for its Phase 3-ready
product, ST-62516 (trimetazidine), a cardiorenal metabolic
modulator. The patent will provide exclusivity through 2037, with
broad claims for the reduction of acute kidney injury in patients
with chronic kidney disease (CKD) undergoing procedures with
contrast dyes.
"We are excited about the continued growth of Saghmos’ patent
estate, with a new Japanese patent, in addition to the issued US
patent and a Notice of Allowance for a second US patent,” commented
Anna Kazanchyan, MD, Founder and CEO of Saghmos Therapeutics.
Saghmos is developing ST-62516 to reduce the risk of Acute
Kidney Injury (AKI) and Major Adverse Cardiac and Kidney Events
(MACKE) after contrast procedures such as percutaneous coronary
intervention (PCI). The company recently announced a collaboration
with the Duke Clinical Research Institute (DCRI) to optimize all
aspects of and plan the operationalization of Saghmos’ Phase 3
study.
Over one million PCI procedures are performed annually in the US
in people with ischemic heart disease, including myocardial
infarction (heart attack). About half of these individuals have
comorbidities such as chronic kidney disease, diabetes, or are aged
75 and older. These comorbidities, in combination with certain
procedure-related factors, impact the safety of PCI and increase
the risk of AKI and MACKE. This is a major unmet medical need with
no FDA-approved drugs available. ST-62516 could benefit all people
undergoing a PCI, not just those with comorbidities, by reducing
the threat of AKI and MACKE after PCI.
About Saghmos Therapeutics
Saghmos Therapeutics is developing ST-62516 (trimetazidine) to
reduce the risk of cardiorenal complications after PCI. The company
has an issued US patent (Patent number 11,123,345) for the
prevention and treatment of acute kidney injury after contrast
procedures, and a Notice of Allowance for an additional patent in
the US. Saghmos recently announced the appointment of Fred Hassan
as Chairman of the Board of Directors and Dr. Stephen Grant as
Chief Regulatory Officer.
Forward looking statements
This press release contains forward-looking statements, pursuant
to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995 and other federal securities laws.
Forward-looking statements contained in this press release include,
but are not limited to, statements regarding Saghmos Therapeutics’
business, intellectual property, clinical and regulatory plans,
commercial potential, and the value and benefits of ST-62516. In
any forward-looking statement in which Saghmos expresses an
expectation or belief as to future results, such expectations or
beliefs are expressed in good faith and are believed to have a
reasonable basis, but there can be no assurance that the statement
or expectation or belief will be achieved. Such forward-looking
statements involve known and unknown risks and uncertainties, which
could cause Saghmos’ actual results to differ materially from those
in the forward-looking statements. Such risks and uncertainties
include, among others, the availability of funds and resources,
uncertainties and changes related to the law and regulatory
process, and general changes in the economic environment. These
forward-looking statements are based on our current expectations.
Saghmos does not undertake any obligation to update these
forward-looking statements, except as required by applicable
laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240514384469/en/
Saghmos Therapeutics, Inc. Anna Kazanchyan, MD Founder
and CEO +1 914 522 3885 anna@saghmos.com or LaVoie Health
Science Katie Dodge Senior Vice President +1 978 360 3151
kdodge@lavoiehealthscience.com